Varenicline (Chantix)

05/01/2016 - "Varenicline, a nicotinic partial agonist, is the most effective treatment for tobacco use disorder. "
05/01/2006 - "Phase II and III trials have yielded promising results suggesting that varenicline could be an important advance in the treatment of nicotine dependence."
10/01/2012 - "Varenicline represents a major advance in the treatment of nicotine addiction and has been shown to be safe and effective to promote abstinence. "
09/01/2009 - "Varenicline, an alpha4beta2-nicotinic partial agonist, is effective for nicotine dependence. "
01/01/2018 - "Identifying predictors of treatment outcome for nicotine use disorders (NUDs) may help improve efficacy of established treatments, like varenicline. "

01/01/2021 - "In a multisite clinical trial, varenicline was effective in reducing drinking in both smoking and non-smoking patients with alcohol dependence. "
03/01/2020 - "Safety and Efficacy of Varenicline for Smoking Cessation in Alcohol-Dependent Smokers in Concurrent Treatment for Alcohol Use Disorder: A Pilot, Randomized Placebo-Controlled Trial."
07/01/2019 - "Efficacy of Varenicline in Patients With Severe Alcohol Dependence: A Pilot Double-Blind Randomized and Controlled Study."
01/01/2018 - "The purpose of this study was to evaluate the efficacy of 12 weeks of varenicline for increasing smoking abstinence rates in smokers with alcohol abuse or dependence. "
09/01/2013 - "Additional studies are needed to confirm the efficacy of varenicline in the treatment of alcohol dependence."

01/01/2016 - "Varenicline appears to be significantly more effective than placebo in assisting with smoking cessation and reduction in people with severe mental illness. "
01/01/2008 - "Varenicline was equally effective in those with and without mental illness. "
01/01/2008 - "In this setting and with group support varenicline appears to improve success rates over those achieved with NRT, and is equally effective and safe in those with and without a mental illness."
07/01/2009 - "Varenicline is a novel treatment for smoking cessation; however, the agent has not been well studied in a population with severe mental illness. "
01/01/2012 - "Prospective trials of varenicline have not reported increased incidence of psychiatric adverse events other than sleep disturbance, but smokers with major mental illness have been excluded from large prospective trials of varenicline to date. "

12/01/2023 - "Objective: To examine the literature pertaining to safety and efficacy of intranasal (IN) varenicline for the treatment of dry eye disease (DED). "
12/01/2023 - "Data Sources: A literature search of PubMed was performed (1985 to January 2022) using the following search terms: varenicline, OC-01, intranasal, and dry eye. "
12/01/2023 - "Intranasal Varenicline: Review of a Novel Formulation for the Treatment of Dry Eye Disease."
07/14/2023 - "The efficacy and safety of varenicline nasal spray for the management of dry eye signs: a systematic review and meta-analysis."
12/13/2021 - "Varenicline nasal spray (Tyrvaya) for dry eye disease."

01/01/2021 - "At each time point, smokers with schizophrenia assigned to varenicline had significantly greater odds of abstinence compared with their matched placebo group, with NNT comparable to the control group. "
01/01/2012 - " CONCLUSIONS: This prospective study suggests that varenicline may be well-tolerated and effective for smoking cessation in combination with group CBT in stable outpatients with schizophrenia, a group with high rates of smoking and smoking-attributable morbidity and mortality."
01/01/2018 - "Conclusion: Despite a limited number of studies included in the meta-analysis, our results suggest that varenicline is an effective and safe drug to assist smoking cessation in patients with schizophrenia. "
12/20/2011 - "However, other case studies and pilot studies have shown varenicline to be a safe and effective treatment for smoking cessation in subjects with schizophrenia. "
01/01/2018 - "To this end, some studies have investigated the efficacy of varenicline for facilitating smoking cessation in schizophrenia patients. "